Leptin as a critical regulator of hepatocellular carcinoma development through modulation of human telomerase reverse transcriptase

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Stefanou, Nikolaos ^a,b   Papanikolaou, Vassilis ^a,b   Furukawa, Yoichi ^c   Nakamura, Yusuke ^c   Tsezou, Aspasia ^a,b  

^a UNIVERSITY OF THESSALY   (Greece)

^b INSTITUTE OF HUMAN PERFORMANCE AND REHABILITATION   (Greece)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; GELATINASE B; HISTONE H3; INTERSTITIAL COLLAGENASE; JANUS KINASE; LEPTIN; LEPTIN RECEPTOR; LIPOSOME; MAX PROTEIN; MESSENGER RNA; MYC PROTEIN; PROTEIN MAD1; SMALL INTERFERING RNA; STAT3 PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; STAT3 PROTEIN, HUMAN; TELOMERASE; TERT PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN HEPG2; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME REGULATION; FEMALE; FLOW CYTOMETRY; GENE CONTROL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER PARENCHYMA; MALE; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN MODIFICATION; UPREGULATION; APOPTOSIS; CELL CYCLE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME IMMUNOASSAY; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; LIVER; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LEPTIN; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, LEPTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR; TELOMERASE; UP-REGULATION;

EID: 77955671392     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-442     Document Type: Article

References (48)

1. Abu-Abid S, Szold A, Klausner J. Obesity and cancer. J Med 2002, 33:73-86.
2. Nair S, Masson A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?. Hepatology 2002, 36:150-155. 10.1053/jhep.2002.33713, 12085359.
3. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature 2006, 443:289-295. 10.1038/nature05026, 16988703.
4. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998, 395:763-770. 10.1038/27376, 9796811.
5. Huang L, Li C. Leptin: a multifunctional hormone. Cell Res 2000, 10:81-92. 10.1038/sj.cr.7290038, 10896170.
6. Sierra-Honigmann MR, Nath AK, Murakami C, Garcia-Gardena G, Papapetropoulos A, Sessa WC, et al. Biological action of leptin as an angiogenic factor. Science 1998, 281:1683-1686. 10.1126/science.281.5383.1683, 9733517.
7. Bouloumie A, Drexler HC, Lafontan M, Busse R. Leptin, the product of ob gene, promotes angiogenesis. Circ Res 1998, 83:1059-1066.
8. La Cava A, Matarese G. The weight of leptin in immunity. Nat Rev Immunol 2004, 4(5):371-379. Review, 10.1038/nri1350, 15122202.
9. Otero M, Lago R, Lago F, Casanueva FF, Dieguez C, Gomez-Reino JJ, et al. Leptin, from fat to inflammation:old questions and new insights. FEBS Lett 2005, 579:295-301. 10.1016/j.febslet.2004.11.024, 15642335.
10. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005, 115:911-919. 10.1016/j.jaci.2005.02.023, 15867843.
11. Margetic S, Garrela C, Pegg GG, Hill RA. Leptin: a review of its peripheral actions and interactions. Int J Obes 2002, 26:1407-1433.
12. Ahima RS, Osei SY. Leptin signaling. Physiol Behav 2004, 81:223-241. 10.1016/j.physbeh.2004.02.014, 15159169.
13. Bromberg J. STAT proteins and oncogenesis. J Clin Invest 2002, 109:1139-1142. 150969, 11994401.
14. Inghirami G, Chiarle R, Simmons JW, Piva R, Schlessinger K, Levy D. New and old functions of STAT3. A pivotal target for individualized treatment of cancer. Cell Cycle 2005, 4(9):1131-1133.
15. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000, 19:2474-2488. 10.1038/sj.onc.1203527, 10851046.
16. Caldwell SM, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology 2004, 127:97-103.
17. Moradpour D, Blum HE. Pathogenesis of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2005, 17:477-483. 10.1097/00042737-200505000-00002, 15827436.
18. Nakayama J, Tahara H, Tahara E, Saito M, Ito K, Nakamura H, et al. Telomerase activation by hTERT in human normal fibroblasts and hepatocellular carcinoma. Nat Genet 1998, 18:65-68. 10.1038/ng0198-65, 9425903.
19. Shimojima M, Komine F, Hisatomi H, Shimiru T, Moriyama M, Arakawa Y. Detection of telomerase activity, telomerase RNA component, and telomerase reverse transcriptase in human hepatocellular carcinoma. Hepatol Res 2004, 29:31-38. 10.1016/j.hepres.2004.02.005, 15135344.
20. Bruix J, Sherman M, Liovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001, 35:421-430. 10.1016/S0168-8278(01)00130-1, 11592607.
21. Green FL, Page DL, Fleming ID, Fruitz A, Balch CM, Haller DG, et al. American Joint Committee on Cancer. Liver (including intrahepatic bile ducts). AJCC cancer Staging Handbook 2002, New York, NY: Springer, 6.
22. Stefanou N, Satra M, Papanikolaou V, Kalala F, Gatselis N, Germenis A, et al. Leptin receptor isoforms mRNA expression in peripheral blood mononuclear cells from patients with chronic viral hepatitis. Exp Biol Med 2006, 231:1653-1663.
23. Satra M, Gatselis N, Iliopoulos D, Zacharoulis D, Dalekos GN, Tsezou A. Real time quantification of human telomerase reverse transcriptase mRNA in liver tissues from patients with hepatocellular cancer and chronic viral hepatitis. Journal of Viral Hepatitis 2007, 14:41-47. 10.1111/j.1365-2893.2006.00769.x, 17212643.
24. Fiorio E, Mercanti A, Terrasi M, Micciolo R, Remo A, Auriemma A, et al. Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysis. BMC Cancer 2008, 8:305. 10.1186/1471-2407-8-305, 2588622, 18945363.
25. Tsezou A, Oikonomou P, Kollia P, Mademtzis I, Kostopoulou E, Messinis I, et al. The role of human telomerase catalytic subunit mRNA expression in cervical dysplasias. Exp Biol Med 2005, 230:263-270.
26. Petridou E, Belechri M, Dessypris N, Koukoulomatis P, Diakopoulos E, Spanos E, et al. Leptin and body mass index in relation to hepatocellular carcinoma risk. Ann Nutr Metab 2002, 46:147-151. 10.1159/000063081, 12169858.
27. Saxena N, Vertino P, Anania F, Sharma D. Leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to cyclin D1 promoter via activation of STAT3. J Biol Chem 2007, 282:13316-13325. 10.1074/jbc.M609798200, 2923657, 17344214.
28. Yin N, Wang D, Zhang H, Yi X, Sun X, Shi B, et al. Molecular mechanisms involved in the growth stimulation of breast cancer cells by leptin. Cancer Res 2004, 64(16):5870-5875. 10.1158/0008-5472.CAN-04-0655, 15313931.
29. Choi JH, Park SH, Leung PC, Choi KC. Expression of leptin receptors and potential effects of leptin on the cell growth and activation of mitogen-activated protein kinases in ovarian cancer cells. J Clin Endocrinol Metab 2004, 90:207-210. 10.1210/jc.2004-0297, 15522945.
30. Yuan SS, Tsai KB, Chung YF, Chan TF, Yeh YT, Tsai LY, et al. Aberrant expression and possible involvement of leptin receptor in endometrial cancer. Gynecol Oncol 2004, 92(3):769-775. 10.1016/j.ygyno.2003.11.043, 14984939.
31. Somansudar P, Frankenberry KA, Skinner H, Vedula G, McFadden DW, Riggs D, et al. Prostate cancer cell proliferation is influenced by leptin. J Surg Res 2004, 118:71-82. 10.1016/j.jss.2004.01.017, 15093720.
32. Garofalo C, Surmacz E. Leptin and cancer. J Cell Physiol 2006, 207:12-22. 10.1002/jcp.20472, 16110483.
33. Birmingham JM, Busik JV, Hansen-Smith FM, Fenton JI. Novel mechanism for obesity-induced colon cancer progression. Carcinogenesis 2009, 30(4):690-697. 10.1093/carcin/bgp041, 2664456, 19221001.
34. Ribatti D, Belloni AS, Nico B, Di Comite M, Crivellato E, Vacca A. Leptin-leptin receptor are involved in angiogenesis in human hepatocellular carcinoma. Peptides 2008, 29(9):1596-1602. 10.1016/j.peptides.2008.05.011, 18573568.
35. Kitade M, Yoshiji H, Kojima H, Ikenaka Y, Noquchi R, Kaji K, et al. Leptin mediated neovascularization is a prerequisite for progression of non-alcoholic steatohepatitis in rats. Hepatology 2006, 44:983-991. 10.1002/hep.21338, 17006938.
36. Wang SN, Chuang YT, Yang SF, Chai CY, Chen WT, Kuo KK, et al. Potential prognostic value of leptin receptor in hepatocellular carcinoma. J Clin Pathol 2006, 59:1267-1271. 10.1136/jcp.2005.033464, 1860536, 16565226.
37. Wang SN, Yeh YT, Yang SF, Chai CY, Lee KT. Potential role of leptin expression in hepatocellular carcinoma. J Clin Pathol 2006, 59(9):930-934. 10.1136/jcp.2005.035477, 1860468, 16565221.
38. Lee CM, Hsu CY, Eng HL, Huang WS, Lu SN, Changchien CS, et al. Telomerase activity and telomerase catalytic subunit in hepatocellular carcinoma. Hepatogastroenterology 2004, 51:796-800.
39. Ren H, Zhao T, Wang X, Gao C, Wang J, Yu M, et al. Leptin upregulates telomerase activity and transcription of human telomerase reverse transcriptase in MCF-7 breast cancer cells. Biochem Bioph Res Co 2010, 394:59-63.
40. Konnikova L, Kruger MM, Kotecki M, Cochran BH. Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer 2003, 3:23. 10.1186/1471-2407-3-23, 212316, 13678425.
41. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21:2000-2008. 10.1038/sj.onc.1205260, 11960372.
42. Konnikova L, Simeone MC, Kruger MM, Kotecki M, Cochran BH. Signal transducer and activator of transcription 3 (STAT3) regulates human telomerase reverse transcriptase (hTERT) expression in human cancer and primary cells. Cancer Res 2005, 65(15):6516-6520. 10.1158/0008-5472.CAN-05-0924, 16061629.
43. Liu L, Lai S, Andrews LG, Tollefsbol TO. Genetic and epigenetic modulation of telomerase activity in development and disease. Gene 2004, 340:1-10. 10.1016/j.gene.2004.06.011, 15556289.
44. Atkinson SP, Hoare SP, Glasspool RM, Keith NW. Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodelling of the hTR and hTERT gene promoters. Cancer Res 2005, 65(17):7585-7590.
45. Iliopoulos D, Satra M, Drakaki A, Poultsides GA, Tsezou A. Epigenetic regulation of hTERT promoter in hepatocellular carcinomas. International Journal of Oncology 2009, 34:391-399.
46. Lawrence T, Hagemann T, Balkwill F. Sex, cytokines, and cancer. Science 2007, 317:51-52. 10.1126/science.1146052, 17615328.
47. Li H, Liu JP. Mechanisms of action of TGF-beta in cancer: evidence for Smad3 as a repressor for the hTERT gene. Ann N Y Acad Sci 2007, 1114:56-68. 10.1196/annals.1396.016, 17934056.
48. Ishii Y, Nakasato Y, Kobayashi S, Yamazaki Y, Aoki T. A study on angiogenesis-related matrix metalloproteinase networks in primary hepatocellular carcinoma. J Exp Clin Cancer Res 2003, 22:461-470.